Pacira BioSciences, Inc. v. Ventis Pharma, Inc.

CourtDistrict Court, C.D. California
DecidedAugust 23, 2024
Docket2:24-cv-07554
StatusUnknown

This text of Pacira BioSciences, Inc. v. Ventis Pharma, Inc. (Pacira BioSciences, Inc. v. Ventis Pharma, Inc.) is published on Counsel Stack Legal Research, covering District Court, C.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Pacira BioSciences, Inc. v. Ventis Pharma, Inc., (C.D. Cal. 2024).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

PACIRA BIOSCIENCES, INC., Plaintiff, Civil Action No. 23-1250-RGA V. VENTIS PHARMA, INC., Defendant.

MEMORANDUM ORDER Before me is Defendant Ventis Pharma’s motion to sever and transfer venue pursuant to 28 U.S.C. § 1404(a). (D.I. 27).! Ihave considered the parties’ briefing. (D.I. 28, 46, 50). I heard oral argument on July 10, 2024.” For the reasons set forth below, Ventis’s motion to transfer is GRANTED. I. BACKGROUND Plaintiff and Ventis are pharmaceutical companies that focus on non-opioid pain management products. (D.I. 1 §§§ 5—6; D.I. 28 at 3). Plaintiff manufactures EXPAREL, which it calls “the first long-lasting non-opioid drug approved by the FDA to reduce post-surgical pain.” (D.I. 1 § 6). Ventis has developed Enduracaine, which it calls “a non-opioid and preservative- free local anesthetic compound product.” (D.I. 28 at 3). Ventis is also a “logistics

' The parties have filed various other motions. Ventis filed a motion to dismiss (D.I. 22), Plaintiff filed a motion for a preliminary injunction (D.I. 13), and Ventis filed a motion for sanctions (D.I. 60). * Citations to the transcript of the argument, which is not yet docketed, are in the format “Hearing Tr. at.”

administrator” for Nubratori, an outsourcing facility that manufactures the drug Endura-KT. (Id.). Plaintiff filed its Complaint on November 1, 2023, alleging that Ventis and InfuSystem Holdings violated the Lanham Act by making false and misleading advertisements. (D.I. 1 □ 108-18). On January 26, 2024, Plaintiff and InfuSystem Holdings entered into a stipulated final judgment, which is “a final adjudication of all claims alleged by Pacira and Defendant InfuSystem in this action.” (D.I. 37 at 4). Ventis, the sole remaining defendant, is incorporated in Delaware. Its principal place of business is in Newport Beach, California. (D.I. 28 at 2). Il. LEGAL STANDARD A district court may, for the convenience of parties and witnesses, “transfer any civil action to any other district or division where it might have been brought” if transferring would be “in the interest of justice.” 28 U.S.C. § 1404(a). “The burden of establishing the need for transfer . . . rests with the movant,” and “the plaintiff's choice of venue should not be lightly disturbed.” Jumara v. State Farm Ins. Co., 55 F.3d 873, 879 (3d Cir. 1995) (citation omitted). A court considering a motion to transfer must first determine “whether the case could have been brought in the district to which the movant wishes to transfer.” Cisco Sys., Inc. v. Ramot at Tel Aviv Univ., Ltd., 2022 WL 16921988, at *3 (D. Del. Nov. 14, 2022) (citing Jumara, 55 F.3d at 878). If venue would have been proper in that district, the court must then determine whether the non-exhaustive list of public and private interest factors set forth in Jumara favors transfer. Jd. at *3-4. To prevail, the movant must show that “the balance of convenience of the parties is strongly in favor” of transfer. Paycom Software, Inc. v. Travelers Cas. & Sur. Co. of Am., 2022 WL 1063845, at *2 (D. Del. Apr. 8, 2022) (quoting Shutte v. Armco Steel Corp., 431 F.2d 22, 25 (3d Cir. 1970)).

The private interests include: (1) plaintiff's forum preference as manifested in the orginal choice; (2) the defendant’s preference; (3) whether the claim arose elsewhere; (4) the convenience of the parties as indicated by their relative physical and financial condition; (5) the convenience of the witnesses—but only to the extent that the witnesses may actually be unavailable for trial in one of the fora; and (6) the location of books and records (similarly limited to the extent that the files could not be produced in the alternative forum). Jumara, 55 F.3d at 879. The public interests include: (7) the enforceability of the judgment; (8) practical considerations that could make the trial easy, expeditious, or inexpensive; (9) the relative administrative difficulty in the two fora resulting from court congestion; (10) the local interest in deciding local controversies at home; (11) the public policies of the fora; and (12) the familiarity of the trial judge with the applicable state law in diversity cases. Jd. at 879-80. Ill. DISCUSSION A. Motion to Sever Ventis asks that I sever InfuSystem Holdings from this case, arguing that InfuSystem Holdings was improperly joined. (D.I. 28 at 9-10). Plaintiff and InfuSystem Holdings entered into a stipulated final judgment on January 26, 2024. (See D.I. 37). Plaintiff thus no longer asserts any claims against InfuSystem Holdings. Ventis’s motion to sever is therefore DISMISSED as moot. B. Motion to Transfer First, I consider whether there is jurisdiction in the transferee court. See Jumara, 55 F.3d at 878-79. A district court may only transfer an action to a “district or division where it might have been brought.” 28 U.S.C. § 1404(a). Ventis argues that this case could have been brought in the Central District of California. (D.I. 28 at 11). Ventis contends that venue is proper in that

district because Ventis resides there and because Plaintiff's claim arose there. (/d.). Plaintiff does not contest that it could have brought this action in the Central District of California. Because Ventis’s principal place of business is in the Central District, I conclude that there is jurisdiction in the transferee court. I thus turn to the private and public factors from Jumara. 1. Plaintiff's Forum Preference Ventis argues that Plaintiff's choice of forum should be given “minimal weight” because Delaware is not Plaintiff's principal place of business. (D.I. 28 at 13-14). Ventis contends that Plaintiff has “no facilities, operations, employees, or presence in Delaware.” (/d. at 14 (quoting Memory Integrity, LLC v. Intel Corp., 2015 WL 632026, at *3 (D. Del. Feb. 13, 2015))). Ventis argues that Plaintiff has no connection to Delaware other than incorporation. (D.I. 50 at 6). Plaintiff argues that its choice to litigate in Delaware weighs against transfer. (D.I. 46 at 4). Plaintiff disagrees that having a principal place of business elsewhere supports transfer. (/d.). Plaintiff contends that argument only applies to foreign entities. (/d. (citing VLSI Tech. LLC v. Intel Corp., 2018 WL 5342650, at *4—5 (D. Del. Oct. 29, 2018))). A plaintiff's choice is generally given “paramount consideration in any determination of a transfer request.” Shutte, 431 F.2d at 25. Here, Plaintiff's choice to sue in Delaware weighs strongly in Plaintiff’s favor, though not as strongly as it would if Plaintiff had its principal place of business in Delaware. See Signal Tech, LLC v. Analog Devices, Inc., 2012 WL 1134723, at *2 (D. Del. Apr. 3, 2012). The record shows that Plaintiff maintains its principal place of business in Florida, and it does not have offices in Delaware. (D.I. 29 3, 5). Accordingly, Plaintiff's choice will be given paramount consideration, but it will not carry the same weight in the balancing of factors as would a similar decision by a plaintiff with a principal place of business in Delaware. Cf Memory Integrity, 2015 WL 632026, at *3 (“The court agrees, in part,

with Intel’s position and concludes that Memory Integrity cannot reap the full benefits of heightened deference as a result of its minimal connection to Delaware.”). 2.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re Link_A_Media Devices Corp.
662 F.3d 1221 (Federal Circuit, 2011)
Affymetrix, Inc. v. Synteni, Inc.
28 F. Supp. 2d 192 (D. Delaware, 1998)
Intellectual Ventures I LLC v. Altera Corp.
842 F. Supp. 2d 744 (D. Delaware, 2012)
Wacoh Co. v. Kionix Inc.
845 F. Supp. 2d 597 (D. Delaware, 2012)
Smart Audio Technologies, LLC v. Apple, Inc.
910 F. Supp. 2d 718 (D. Delaware, 2012)
Shutte v. Armco Steel Corp.
431 F.2d 22 (Third Circuit, 1970)

Cite This Page — Counsel Stack

Bluebook (online)
Pacira BioSciences, Inc. v. Ventis Pharma, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/pacira-biosciences-inc-v-ventis-pharma-inc-cacd-2024.